Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Receives $78.60 Consensus Price Target from Analysts

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) has received an average rating of “Moderate Buy” from the fifteen research firms that are currently covering the stock, MarketBeat.com reports. Three equities research analysts have rated the stock with a hold recommendation, eleven have assigned a buy recommendation and one has issued a strong buy recommendation on the company. The average 1 year price target among brokerages that have covered the stock in the last year is $77.93.

Several research analysts have issued reports on APLS shares. Mizuho reiterated a “neutral” rating and issued a $60.00 price objective on shares of Apellis Pharmaceuticals in a research report on Wednesday, March 27th. Robert W. Baird reiterated an “outperform” rating and issued a $81.00 price objective on shares of Apellis Pharmaceuticals in a research report on Tuesday, February 6th. Raymond James raised their price target on Apellis Pharmaceuticals from $67.00 to $106.00 and gave the company a “strong-buy” rating in a research report on Thursday, January 11th. UBS Group raised their price target on Apellis Pharmaceuticals from $87.00 to $89.00 and gave the company a “buy” rating in a research report on Monday, March 4th. Finally, JPMorgan Chase & Co. raised their price target on Apellis Pharmaceuticals from $78.00 to $79.00 and gave the company an “overweight” rating in a research report on Wednesday, March 6th.

Apellis Pharmaceuticals Trading Up 0.0 %

NASDAQ:APLS opened at $47.53 on Monday. The stock has a fifty day moving average price of $59.71 and a two-hundred day moving average price of $57.04. The stock has a market capitalization of $5.73 billion, a price-to-earnings ratio of -10.61 and a beta of 0.88. The company has a debt-to-equity ratio of 0.48, a quick ratio of 2.50 and a current ratio of 3.10. Apellis Pharmaceuticals has a 1 year low of $19.83 and a 1 year high of $94.75.

Apellis Pharmaceuticals (NASDAQ:APLS) last released its quarterly earnings data on Tuesday, February 27th. The company reported ($0.73) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.73). The firm had revenue of $146.38 million during the quarter, compared to analysts’ expectations of $143.34 million. Apellis Pharmaceuticals had a negative return on equity of 178.60% and a negative net margin of 133.34%. Apellis Pharmaceuticals’s revenue was up 545.9% compared to the same quarter last year. During the same quarter in the prior year, the business posted ($1.50) earnings per share. As a group, sell-side analysts anticipate that Apellis Pharmaceuticals will post -1.33 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, CEO Cedric Francois sold 250,000 shares of Apellis Pharmaceuticals stock in a transaction dated Friday, March 1st. The stock was sold at an average price of $64.11, for a total transaction of $16,027,500.00. Following the completion of the sale, the chief executive officer now owns 313,662 shares in the company, valued at approximately $20,108,870.82. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. In other Apellis Pharmaceuticals news, General Counsel David O. Watson sold 781 shares of the firm’s stock in a transaction dated Monday, February 12th. The stock was sold at an average price of $67.77, for a total value of $52,928.37. Following the sale, the general counsel now directly owns 103,390 shares of the company’s stock, valued at approximately $7,006,740.30. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, CEO Cedric Francois sold 250,000 shares of the firm’s stock in a transaction dated Friday, March 1st. The stock was sold at an average price of $64.11, for a total value of $16,027,500.00. Following the completion of the sale, the chief executive officer now directly owns 313,662 shares in the company, valued at $20,108,870.82. The disclosure for this sale can be found here. In the last quarter, insiders sold 406,651 shares of company stock worth $25,130,257. 7.50% of the stock is owned by corporate insiders.

Institutional Trading of Apellis Pharmaceuticals

Hedge funds have recently added to or reduced their stakes in the business. Future Financial Wealth Managment LLC acquired a new stake in Apellis Pharmaceuticals in the 1st quarter worth about $29,000. First Horizon Advisors Inc. lifted its stake in shares of Apellis Pharmaceuticals by 69.0% in the 3rd quarter. First Horizon Advisors Inc. now owns 649 shares of the company’s stock valued at $25,000 after purchasing an additional 265 shares in the last quarter. Covestor Ltd lifted its stake in shares of Apellis Pharmaceuticals by 564.2% in the 3rd quarter. Covestor Ltd now owns 797 shares of the company’s stock valued at $30,000 after purchasing an additional 677 shares in the last quarter. Stephens Consulting LLC acquired a new position in shares of Apellis Pharmaceuticals in the 3rd quarter valued at about $38,000. Finally, US Bancorp DE lifted its stake in shares of Apellis Pharmaceuticals by 391.2% in the 1st quarter. US Bancorp DE now owns 1,110 shares of the company’s stock valued at $56,000 after purchasing an additional 884 shares in the last quarter. 96.29% of the stock is owned by institutional investors and hedge funds.

Apellis Pharmaceuticals Company Profile

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).